Christophe Legendre

List of Publications by Year
in descending order

192	10,818	34105	36028
papers	citations	52 h-index	97 g-index

208	208	208	9113
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Complement-Binding Anti-HLA Antibodies and Kidney-Allograft Survival. New England Journal of Medicine, 2013, 369, 1215-1226.	27.0	746
2	Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal Transplantation. New England Journal of Medicine, 1999, 340, 1462-1470.	27.0	681
3	Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney International, 2015, 87, 1061-1073.	5.2	342
4	Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet, The, 2013, 381, 313-319.	13.7	308
5	Outcome of Subclinical Antibody-Mediated Rejection in Kidney Transplant Recipients with Preformed Donor-Specific Antibodies. American Journal of Transplantation, 2009, 9, 2561-2570.	4.7	290
6	Each additional hour of cold ischemia time significantly increases the risk of graft failure and mortality following renal transplantation. Kidney International, 2015, 87, 343-349.	5.2	287
7	IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury. Journal of the American Society of Nephrology: JASN, 2016, 27, 293-304.	6.1	244
8	Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts. Journal of the American Society of Nephrology: JASN, 2015, 26, 1721-1731.	6.1	243
9	HARMFUL LONG-TERM IMPACT OF HEPATITIS C VIRUS INFECTION IN KIDNEY TRANSPLANT RECIPIENTS. Transplantation, 1998, 65, 667-670.	1.0	233
10	Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. American Journal of Kidney Diseases, 2016, 68, 84-93.	1.9	230
11	Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal Transplantation. American Journal of Transplantation, 2012, 12, 3337-3354.	4.7	223
12	Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients. Journal of the American Society of Nephrology: JASN, 2017, 28, 1912-1923.	6.1	208
13	Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015. Kidney International, 2018, 94, 964-973.	5.2	198
14	Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2018, 29, 1979-1991.	6.1	193
15	Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. BMJ: British Medical Journal, 2019, 366, l4923.	2.3	191
16	Factors influencing long-term outcome after kidney transplantation. Transplant International, 2014, 27, 19-27.	1.6	176
17	A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Science Translational Medicine, 2014, 6, 256ra136.	12.4	172
18	New insights into postrenal transplant hemolytic uremic syndrome. Nature Reviews Nephrology, 2011, 7, 23-35.	9.6	169

#	Article	IF	Citations
19	Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. BMJ, The, 2015, 351, h3557.	6.0	146
20	Cytomegalovirus Incidence Between Everolimus Versus Mycophenolate in De Novo Renal Transplants: Pooled Analysis of Three Clinical Trials. American Journal of Transplantation, 2011, 11, 2453-2462.	4.7	135
21	Combined Posttransplant Prophylactic IVIg/Anti-CD 20/Plasmapheresis in Kidney Recipients With Preformed Donor-Specific Antibodies: A Pilot Study. Transplantation, 2010, 89, 1403-1410.	1.0	133
22	Disparities in Acceptance of Deceased Donor Kidneys Between the United States and France and Estimated Effects of Increased US Acceptance. JAMA Internal Medicine, 2019, 179, 1365.	5.1	125
23	Kaposi sarcoma in transplantation. Transplantation Reviews, 2008, 22, 252-261.	2.9	123
24	Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. Kidney International, 2019, 96, 189-201.	5.2	117
25	A Simple Clinico-Histopathological Composite Scoring System Is Highly Predictive of Graft Outcomes in Marginal Donors. American Journal of Transplantation, 2008, 8, 2325-2334.	4.7	116
26	Sirolimus Conversion for Patients with Posttransplant Kaposi's Sarcoma. American Journal of Transplantation, 2006, 6, 2164-2168.	4.7	114
27	Urinary C-X-C Motif Chemokine 10 Independently Improves the Noninvasive Diagnosis of Antibodyâ€“Mediated Kidney Allograft Rejection. Journal of the American Society of Nephrology: JASN, 2015, 26, 2840-2851.	6.1	112
28	Value of Donorâ€“Specific Antiâ€“HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss. Journal of the American Society of Nephrology: JASN, 2017, 28, 702-715.	6.1	111
29	HUMAN HERPES VIRUS-8 AND OTHER RISK FACTORS FOR KAPOSI'S SARCOMA IN KIDNEY TRANSPLANT RECIPIENTS1. Transplantation, 1999, 67, 1236-1242.	1.0	107
30	Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept. Transplantation, 2021, 105, e94-e95.	1.0	105
31	mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplantation Reviews, 2008, 22, 125-130.	2.9	103
32	Specificity of Histological Markers of Longâ€Term CNI Nephrotoxicity in Kidneyâ€Transplant Recipients Under Lowâ€Dose Cyclosporine Therapy. American Journal of Transplantation, 2011, 11, 2635-2646.	4.7	101
33	Effects of vitamin D supplementation on the calciumâ€“phosphate balance in renal transplant patients. Kidney International, 2009, 75, 646-651.	5.2	99
34	Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. American Journal of Transplantation, 2019, 19, 3018-3034.	4.7	97
35	Prognostic Value of Quantitative Kaposi Sarcomaâ€“Associated Herpesvirus Load in Posttransplantation Kaposi Sarcoma. Journal of Infectious Diseases, 2002, 186, 110-113.	4.0	93
36	C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. Kidney International, 2017, 92, 1232-1241.	5.2	93

#	Article	IF	Citations
37	Donor-Specific Antibodies Accelerate Arteriosclerosis after Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2011, 22, 975-983.	6.1	88
38	Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. American Journal of Transplantation, 2017, 17, 1370-1379.	4.7	85
39	Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept. American Journal of Transplantation, 2021, 21, 4043-4051.	4.7	84
40	Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN. Journal of the American Society of Nephrology: JASN, 2017, 28, 1603-1613.	6.1	83
41	A useful scoring system for the prediction and management of delayed graft function following kidney transplantation from cadaveric donors. Kidney International, 2014, 86, 1130-1139.	5.2	82
42	Improving Outcomes for Solid-Organ Transplant Recipients At Risk from Cytomegalovirus Infection: Late-Onset Disease and Indirect Consequences. Clinical Infectious Diseases, 2008, 46, 732-740.	5.8	81
43	Recurrence of nephrotic syndrome after transplantation in a mixed population of children and adults: course of glomerular lesions and value of the Columbia classification of histological variants of focal and segmental glomerulosclerosis (FSGS). Nephrology Dialysis Transplantation, 2010, 25, 1321-1328.	0.7	81
44	T cellâ€“mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts. American Journal of Transplantation, 2018, 18, 377-390.	4.7	76
45	Donor-Estimated GFR as an Appropriate Criterion for Allocation of ECD Kidneys into Single or Dual Kidney Transplantation. American Journal of Transplantation, 2009, 9, 2542-2551.	4.7	75
46	B7â€“1 Blockade Does Not Improve Postâ€“Transplant Nephrotic Syndrome Caused by Recurrent FSGS. Journal of the American Society of Nephrology: JASN, 2016, 27, 2520-2527.	6.1	75
47	COVID-19 severity in kidney transplant recipients is similar to nontransplant patients with similar comorbidities. American Journal of Transplantation, 2021, 21, 1285-1294.	4.7	69
48	Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies. American Journal of Transplantation, 2019, 19, 2865-2875.	4.7	67
49	Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma. Blood, 2006, 108, 3871-3880.	1.4	66
50	Kidney Transplant in Black Recipients: Are African Europeans Different from African Americans?. American Journal of Transplantation, 2005, 5, 2682-2687.	4.7	64
51	Response to treatment and long-term outcomes in kidney transplant recipients with acute T cellâ€“mediated rejection. American Journal of Transplantation, 2019, 19, 1972-1988.	4.7	60
52	Posttransplant Prophylactic Intravenous Immunoglobulin in Kidney Transplant Patients at High Immunological Risk: A Pilot Study. American Journal of Transplantation, 2007, 7, 1185-1192.	4.7	55
53	To Biopsy or Not to Biopsy? Should We Screen the Histology of Stable Renal Grafts?. Transplantation, 2007, 84, 671-676.	1.0	54
54	The spectrum of kidney biopsies in hospitalized patients with COVID-19, acute kidney injury and/or proteinuria. Nephrology Dialysis Transplantation, 2021, 36, 1253-1262.	0.7	54

#	Article	IF	Citations
55	Effect of an Early Switch to Belatacept Among Calcineurin Inhibitorâ€“Intolerant Graft Recipients of Kidneys From Extendedâ€€Criteria Donors. American Journal of Transplantation, 2016, 16, 2181-2186.	4.7	52
56	Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype. American Journal of Transplantation, 2016, 16, 2670-2675.	4.7	51
57	Genome-Wide Association Study of Acute Renal Graft Rejection. American Journal of Transplantation, 2017, 17, 201-209.	4.7	50
58	COVID-19 in Patients on Maintenance Dialysis in the Paris Region. Kidney International Reports, 2020, 5, 1535-1544.	0.8	49
59	Antiphospholipid syndrome and kidney disease. Kidney International, 2017, 91, 34-44.	5.2	44
60	mTOR inhibitors may benefit kidney transplant recipients with mitochondrial diseases. Kidney International, 2019, 95, 455-466.	5.2	44
61	Pharmacogenetics in Solid Organ Transplantation: Present Knowledge and Future Perspectives. Transplantation, 2004, 78, 311-315.	1.0	43
62	Circulating donor-specific anti-HLA antibodies areÂaÂmajor factor in premature and acceleratedÂallograft fibrosis. Kidney International, 2017, 92, 729-742.	5.2	43
63	Conversion to Belatacept in Maintenance Kidney Transplant Patients. Transplantation, 2018, 102, 1545-1552.	1.0	43
64	Recurrence from primary and secondary glomerulopathy after renal transplant. Transplant International, 2012, 25, 812-824.	1.6	42
65	Determinants and Outcomes of Accelerated Arteriosclerosis. Circulation Research, 2015, 117, 470-482.	4.5	41
66	Epitope load identifies kidney transplant recipients at risk of allosensitization following minimization of immunosuppression. Kidney International, 2019, 95, 1471-1485.	5.2	40
67	Trajectories of glomerular filtration rate and progression to end stage kidney disease afterÂkidney transplantation. Kidney International, 2021, 99, 186-197.	5.2	40
68	Assessment of the Utility of Kidney Histology as a Basis for Discarding Organs in the United States: A Comparison of International Transplant Practices and Outcomes. Journal of the American Society of Nephrology: JASN, 2021, 32, 397-409.	6.1	40
69	Eculizumab in renal transplantation. Transplantation Reviews, 2013, 27, 90-92.	2.9	39
70	Risk of Antibody-Mediated Rejection in Kidney Transplant Recipients With Anti-HLA-C Donor-Specific Antibodies. American Journal of Transplantation, 2014, 14, 1439-1445.	4.7	39
71	Restricted specificity of peripheral alloreactive memory B cells in HLA-sensitized patients awaiting a kidney transplant. Kidney International, 2015, 87, 1230-1240.	5.2	39
72	The emerging role of complement inhibitors in transplantation. Kidney International, 2015, 88, 967-973.	5.2	39

#	Article	IF	Citations
73	Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B. PLoS Neglected Tropical Diseases, 2016, 10, e0004304.	3.0	38
74	Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection. Kidney International, 2018, 94, 773-787.	5.2	38
75	Development and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection. American Journal of Transplantation, 2020, 20, 3462-3476.	4.7	38
76	Prevalence and Predictors of Early Cardiovascular Events after Kidney Transplantation: Evaluation of Pre-Transplant Cardiovascular Work-Up. PLoS ONE, 2015, 10, e0131237.	2.5	38
77	Outcome of Kidney Transplantations Performed With Preformed Donor-Specific Antibodies of Unknown Etiology. American Journal of Transplantation, 2014, 14, 193-201.	4.7	37
78	Post-Transplant Natural Antibodies Associate with Kidney Allograft Injury and Reduced Long-Term Survival. Journal of the American Society of Nephrology: JASN, 2018, 29, 1761-1770.	6.1	36
79	Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival. Kidney International, 2014, 85, 182-190.	5.2	35
80	Dual Kidney Transplantation: Is It Worth It?. Transplantation, 2017, 101, 488-497.	1.0	32
81	Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study. Journal of the American Academy of Dermatology, 2019, 81, 448-455.	1.2	31
82	Impact of estimation versus direct measurement of predonation glomerular filtration rate on the eligibility of potential living kidney donors. Kidney International, 2019, 95, 896-904.	5.2	31
83	Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept. American Journal of Transplantation, 2021, 21, 2448-2458.	4.7	31
84	Estimated or Measured GFR in Living Kidney Donors Work-up?. American Journal of Transplantation, 2016, 16, 3024-3032.	4.7	30
85	Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooledpost hocanalysis. Transplant International, 2017, 30, 1275-1283.	1.6	30
86	Decline and loss of antiâ€“SARS-CoV-2 antibodies in kidney transplant recipients inÂthe 6 months following SARS-CoV-2 infection. Kidney International, 2021, 99, 486-488.	5.2	30
87	Membranous Nephropathy Posttransplantation: An Update of the Pathophysiology and Management. Transplantation, 2019, 103, 1990-2002.	1.0	29
88	De Novo Donor-Specific Human Leukocyte Antigen Antibodies in Nonsensitized Kidney Transplant Recipients After T Cell-Mediated Rejection. Transplantation, 2015, 99, 965-972.	1.0	28
89	The age-calibrated measured glomerular filtrationÂrate improves living kidney donationÂselection process. Kidney International, 2018, 94, 616-624.	5.2	28
90	Excellent long-term outcome of renal transplantation in cystinosis patients. Orphanet Journal of Rare Diseases, 2015, 10, 90.	2.7	27

#	Article	IF	Citations
91	AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game. Lupus, 2015, 24, 227-230.	1.6	27
92	Pathogenesis of non-HLA antibodies in solid organ transplantation: Where do we stand?. Human Immunology, 2016, 77, 1055-1062.	2.4	26
93	Solid Organ Transplantation in the Era of COVID-19: Lessons from France. Transplantation, 2021, 105, 61-66.	1.0	26
94	Propensity scoreâ€“based comparison of the graft failure risk between kidney transplant recipients of standard and expanded criteria donor grafts: Toward increasing the pool of marginal donors. American Journal of Transplantation, 2018, 18, 1151-1157.	4.7	25
95	Dynamic prediction of renal survival among deeply phenotyped kidney transplant recipients using artificial intelligence: an observational, international, multicohort study. The Lancet Digital Health, 2021, 3, e795-e805.	12.3	25
96	Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection. Kidney International, 2022, 101, 1290-1293.	5.2	25
97	Reversal of Arterial Stiffness and Maladaptative Arterial Remodeling After Kidney Transplantation. Journal of the American Heart Association, 2017, 6, .	3.7	24
98	HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. Kidney International, 2021, 99, 671-685.	5.2	24
99	Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study. BMJ Open, 2021, 11, e052138.	1.9	24
100	Long-term CD4 lymphopenia is associated with accelerated decline of kidney allograft function. Nephrology Dialysis Transplantation, 2016, 31, 487-495.	0.7	23
101	Preemptive second kidney transplantation is associated with better graft survival compared with non-preemptive second transplantation: a multicenter French 2000-2014 cohort study. Transplant International, 2018, 31, 408-423.	1.6	22
102	A personalized follow-up of kidney transplant recipients using video conferencing based on a 1-year scoring system predictive of long term graft failure (TELEGRAFT study): protocol for a randomized controlled trial. BMC Nephrology, 2015, 16, 6.	1.8	21
103	Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence. Transplantation, 2017, 101, 2924-2930.	1.0	21
104	Efficacy and Safety of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Recipients: Pooled Data From Three 12-Month Multicenter, Open-Label, Prospective Studies. Transplantation Proceedings, 2007, 39, 1386-1391.	0.6	20
105	Longâ€term outcome of methylmalonic aciduria after kidney, liver, or combined liverâ€kidney transplantation: The French experience. Journal of Inherited Metabolic Disease, 2020, 43, 234-243.	3.6	20
106	Reassessment of the clinical impact of preformed donor-specific anti-HLA-Cw antibodies in kidney transplantation. American Journal of Transplantation, 2020, 20, 1365-1374.	4.7	20
107	TRANSFORM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation. Open Access Journal of Clinical Trials, 2014, , 45.	1.5	19
108	The costimulatory receptor B7-1 is not induced in injured podocytes. Kidney International, 2016, 90, 1037-1044.	5.2	18

#	Article	IF	Citations
109	Conversion From Calcineurin Inhibitors to Belatacept in HLA-sensitized Kidney Transplant Recipients With Low-level Donor-specific Antibodies. Transplantation, 2019, 103, 2150-2156.	1.0	18
110	Acquired Flucytosine Resistance during Combination Therapy with Caspofungin and Flucytosine for Candida glabrata Cystitis. Antimicrobial Agents and Chemotherapy, 2016, 60, 662-665.	3.2	17
111	Association of mGFR of the Remaining Kidney Divided by Its Volume before Donation with Functional Gain in mGFR among Living Kidney Donors. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1369-1376.	4.5	16
112	Temporal virus serological profiling of kidney graft recipients using VirScan. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10899-10904.	7.1	16
113	Efficacy and Safety of Direct Oral Anticoagulants in Kidney Transplantation: A Single-center Pilot Experience. Transplantation, 2020, 104, 2625-2631.	1.0	15
114	Central nervous system complications in adult cystinosis patients. Journal of Inherited Metabolic Disease, 2020, 43, 348-356.	3.6	14
115	Use of computed tomography assessed kidney length to predict split renal GFR in living kidney donors. European Radiology, 2017, 27, 651-659.	4.5	13
116	Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening. American Journal of Transplantation, 2017, 17, 1008-1019.	4.7	13
117	Dynamic predictions of long-term kidney graft failure: an information tool promoting patient-centred care. Nephrology Dialysis Transplantation, 2019, 34, 1961-1969.	0.7	13
118	GFR Assessment of Living Kidney Donors Candidates. Transplantation, 2019, 103, 1086-1093.	1.0	13
119	Prognosis of Invasive Aspergillosis in Kidney Transplant Recipients: A Case-Control Study. Transplantation Direct, 2016, 2, e90.	1.6	12
120	Poor Patient and Graft Outcome After Induction Treatment by Antithymocyte Globulin in Recipients of a Kidney Graft After Nonrenal Organ Transplantation. Transplantation Direct, 2018, 4, e357.	1.6	12
121	Safety of renal transplantation in patients with bipolar or psychotic disorders: a retrospective study. Transplant International, 2018, 31, 377-385.	1.6	12
122	Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients. Transplantation Reviews, 2019, 33, 191-199.	2.9	12
123	Should kidney allografts from old donors be allocated only to old recipients?. Transplant International, 2020, 33, 849-857.	1.6	12
124	Renal transplantation outcomes in obese patients: a French cohort-based study. BMC Nephrology, 2021, 22, 79.	1.8	12
125	Mortality Prediction after the First Year of Kidney Transplantation: An Observational Study on Two European Cohorts. PLoS ONE, 2016, 11, e0155278.	2.5	12
126	Paraganglioma of the bladder in a kidney transplant recipient: A case report. Molecular and Clinical Oncology, 2017, 6, 553-555.	1.0	11

#	Article	IF	Citations
127	Association of blood bicarbonate and pH with mineral metabolism disturbance and outcome after kidney transplantation. American Journal of Transplantation, 2020, 20, 1063-1075.	4.7	11
128	Temporal trends in living kidney donation in France between 2007 and 2017. Nephrology Dialysis Transplantation, 2021, 36, 730-738.	0.7	11
129	Lung cancer in renal transplant recipients: A case-control study. Lung Cancer, 2017, 111, 96-100.	2.0	10
130	Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: a case-controlled study. Transplantation Proceedings, 1993, 25, 1431-3.	0.6	10
131	The sexual dimorphism of kidney growth in mice and humans. Kidney International, 2022, 102, 78-95.	5.2	10
132	Proteinuria in kidney transplantation: an ongoing story. Nature Reviews Nephrology, 2013, 9, 251-252.	9.6	9
133	The Association Between Fibroblast Growth FactorÂ23 and Renal Transplantation Outcome IsÂModified by Follow-up Duration and GlomerularÂFiltration Rate Assessment Method. Kidney International Reports, 2017, 2, 881-892.	0.8	9
134	The role of complement inhibition in kidney transplantation. British Medical Bulletin, 2017, 124, 1-13.	6.9	9
135	Comparison of graft and patient survival according to the transplantation centre policy for 1-year screening biopsy among stable kidney recipients: a propensity score-based study. Nephrology Dialysis Transplantation, 2019, 34, 703-711.	0.7	9
136	Deciphering the Prognostic and Predictive Value of Urinary CXCL10 in Kidney Recipients With BK Virus Reactivation. Frontiers in Immunology, 2020, 11, 604353.	4.8	9
137	The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation. European Journal of Health Economics, 2005, 6, 172-182.	2.8	8
138	Determination of Lowest Possible Creatinine in Living-Donor Kidney Renal Transplant Recipients Based on Donor Kidney Function. Transplantation, 2008, 86, 558-563.	1.0	8
139	PREventing Delayed Graft Function by Driving Immunosuppressive InduCtion Treatment (PREDICT-DGF): study protocol for a randomized controlled trial. Trials, 2015, 16, 282.	1.6	8
140	No clinical benefit of rapid versus gradual tapering of immunosuppression to treat sustained <scp>BK</scp> virus viremia after kidney transplantation: a singleâ€center experience. Transplant International, 2019, 32, 481-492.	1.6	8
141	Comparison of machine perfusion versus cold storage in kidney transplant recipients from expanded criteria donors: a cohort-based study. Nephrology Dialysis Transplantation, 2020, 35, 1051-1059.	0.7	8
142	Time-dependent lymphocyte count after transplantation is associated with higher risk of graft failure and death. Kidney International, 2021, 99, 1189-1201.	5.2	8
143	Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: Results of a nationwide study. American Journal of Transplantation, 2021, 21, 3021-3033.	4.7	8
144	Induction therapy in kidney transplant recipients: Description of the practices according to the calendar period from the French multicentric DIVAT cohort. PLoS ONE, 2020, 15, e0240929.	2.5	8

#	Article	IF	Citations
145	CRISPR/Cas9-Engineered HLA-Deleted Glomerular Endothelial Cells as a Tool to Predict Pathogenic Non-HLA Antibodies in Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2021, 32, 3231-3251.	6.1	8
146	Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: A case-controlled study. Journal of Medical Virology, 1993, 41, 118-122.	5.0	7
147	Renal safety of high-dose, sucrose-free intravenous immunoglobulin in kidney transplant recipients: an observational study. Transplant International, 2016, 29, 1205-1215.	1.6	7
148	Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus. Transplant Infectious Disease, 2018, 20, e12846.	1.7	7
149	Encrusted Urinary Tract Infections Due to Corynebacteria Species. Kidney International Reports, 2021, 6, 179-186.	0.8	7
150	CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen. Transplant International, 2016, 29, 184-195.	1.6	6
151	What is the significance of end-stage renal disease risk estimation in living kidney donors?. Transplant International, 2017, 30, 799-806.	1.6	6
152	Osmoregulation Performance and Kidney Transplant Outcome. Journal of the American Society of Nephrology: JASN, 2019, 30, 1282-1293.	6.1	6
153	PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of) Tj ETQq1 1 0.784314 rgBT /Overlock 1 controlled study. Trials, 2019, 20, 375.	1.6	6
154	Comparison of Postdonation Kidney Function Between Caucasian Donors and Low-risk APOL1 Genotype Living Kidney Donors of African Ancestry. Transplantation, 2018, 102, e462-e463.	1.0	5
155	Dissociation of humoral and cellular immune responses in kidney transplant recipients with EBV mucocutaneous ulcer. Transplant Infectious Disease, 2021, 23, e13552.	1.7	5
156	Ravulizumab for the Treatment of aHUS in Adults: Improving Quality of Life. Kidney International Reports, 2021, 6, 1489-1491.	0.8	5
157	Kidney transplantation from expanded criteria donors: an increased risk of urinary complications â€“ the UriNary Complications Of Renal Transplant (UNyCORT) study. BJU International, 2022, 129, 225-233.	2.5	5
158	The First Transplant Kidney Biopsy Ever Performed. American Journal of Transplantation, 2013, 13, 1367-1368.	4.7	4
159	Conversion From Belatacept to Another Immunosuppressive Regimen in Maintenance Kidney-Transplantation Patients. Kidney International Reports, 2020, 5, 2195-2201.	0.8	4
160	The weekend effect in kidney transplantation outcomes: a French cohortâ€based study. Transplant International, 2020, 33, 1030-1039.	1.6	4
161	Timing of Kidney Clamping and Deceased Donor Kidney Transplant Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1704-1714.	4.5	4
162	Sequential measurements of urinary albumin in recipients of renal allografts. Clinical Chemistry, 1991, 37, 472-473.	3.2	3

#	Article	IF	Citations
163	Generation of Catalytic Antibodies Is an Intrinsic Property of an Individualâ€™s Immune System: A Study on a Large Cohort of Renal Transplant Patients. Journal of Immunology, 2016, 196, 4075-4081.	0.8	3
164	Lifetime ESKD risk stratification for living kidney donor studies. American Journal of Transplantation, 2019, 19, 2658-2659.	4.7	3
165	Lack of impact of pre-emptive deceased-donor kidney transplantation on graft outcomes: a propensity score-based study. Nephrology Dialysis Transplantation, 2019, 34, 886-891.	0.7	3
166	Predictive value of mixed antigen screen beads in preâ€transplant assessment of HLA immunization in solid organ transplant recipients. Clinical Transplantation, 2020, 34, e14002.	1.6	3
167	Management of post-transplant recurrent focal and segmental glomerulosclerosis. Nephrology Dialysis Transplantation, 2021, 36, 1994-1996.	0.7	3
168	Ig-responsive relapsing inflammatory syndrome following COVID-19 in a kidney transplant recipient. Kidney International, 2021, 99, 767-768.	5.2	3
169	Living kidney donor evaluation for all candidates with normal estimated GFR for age. Transplant International, 2021, 34, 1123-1133.	1.6	3
170	Antibody-mediated vascular rejection of kidney allograft: characterization of different kidney allograft rejection phenotypes via histology, C4d deposition and donor-specific antibodies. Clinical and Experimental Immunology, 2014, 178, 59-60.	2.6	2
171	A Test Identifying Biomarkers ofÂImmunosuppression-Related Adverse Events inÂKidney Transplant Recipients. Kidney International Reports, 2019, 4, 1664-1665.	0.8	2
172	Baseline graft status is a critical predictor of kidney graft failure after diarrhoea. Nephrology Dialysis Transplantation, 2019, 34, 1597-1604.	0.7	2
173	Outcomes of kidneyâ€transplanted patients with history of intestinal reconstruction of the urinary tract. BJUI Compass, 2022, 3, 75-85.	1.3	2
174	Editorial: Transplantation of Marginal Organsâ€”Immunological Aspects and Therapeutic Perspectives. Frontiers in Immunology, 2020, 11, 612576.	4.8	2
175	Erythrocytosis associated with IgA nephropathy. EBioMedicine, 2022, 75, 103785.	6.1	2
176	Poor kidney graft survival in anorexia nervosa patients. Eating and Weight Disorders, 2021, 26, 1447-1455.	2.5	1
177	A kidney discard decision strategy based on zeroâ€time histology analysis could lead to an unjustified increase in the organ turndown rate among ECD. Transplant International, 2021, 34, 1506-1516.	1.6	1
178	The Case | Membranous nephropathy after alemtuzumab treatment. Kidney International, 2021, 100, 249-250.	5.2	1
179	Cohort study: â€œOutcomes of kidney transplantation in patients with prosthetic heart valvesâ€• Transplant International, 2021, 34, 2297-2304.	1.6	1
180	COVID-19: A One-center Experience in Paris. Transplantation Direct, 2021, 7, e647.	1.6	1

#	Article	IF	Citations
181	Long-term survival benefit from dual kidney transplantation using kidneys from donors with very extended criteriaâ€"a French cohort between 2002 and 2014. Nephrology Dialysis Transplantation, 2022, 37, 982-990.	0.7	1
182	First dose OKT3-induced release of endothelin in renal transplant recipients. Nephrology Dialysis Transplantation, 0, , .	0.7	0
183	Response to: â€œRenal allograft histology at 10Âyears after transplantation in the tacrolimus era: Evidence of pervasive chronic injuryâ€. American Journal of Transplantation, 2018, 18, 1292-1292.	4.7	0
184	FP742THE IMPACT OF AGE ON ACCEPTABLE MEASURED GFR FOR LIVING KIDNEY DONATION. Nephrology Dialysis Transplantation, 2018, 33, i296-i296.	0.7	0
185	FO051THE IMPACT OF GFR EVALUATION TECHNIQUE ON LIVING KIDNEY DONATION ELIGIBILITY. Nephrology Dialysis Transplantation, 2018, 33, i39-i40.	0.7	0
186	The Case | Posttransplant upper limb inflammatory nodules. Kidney International, 2019, 95, 721-722.	5.2	0
187	FC 055PERCENTILES OF NORMAL MEASURED GLOMERULAR FILTRATION RATE BASED ON DATA FROM LIVING KIDNEY DONORS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
188	The Case | Cardiac tamponade in a kidney transplant recipient with chronic inflammation. Kidney International, 2021, 100, 487-488.	5.2	0
189	Outcome of pretransplant melanoma after solid organ transplantation: an observational study. Transplant International, 2021, 34, 2154-2165.	1.6	0
190	Cancer After Kidney Transplantation. , 2017, , 525-542.		0
191	MO1021: Long-Term Outcomes After Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant: A Matched Cohort Study. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
192	FC 105: Multidimensional Prognostication Tool for Kidney Transplant Patient Survival: The Mortality Mbox. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0